Journal of Nanomedicine & Biotherapeutic Discovery
ISSN: 2155-983X
OPEN ACCESS Freely available online
Short Communication

Role of Nanomedicine in Drug Delivery System

Ruojiee Zhang*

Department of Pharmaceutics, University of Cairo, Giza, Governorate, Egypt

ABOUT THE STUDY

Nanomedicine is a new type of treatment that focuses on improving the effectiveness of the medication while minimizing negative side effects on healthy tissues. Drug resistance in cancer is a complex process that includes several pathways. Here, we go over the main types of medication resistance and the fresh ways that nanomedicines might help tackle these problems. Drug selection for individualized patient therapy may be made considerably more intensive and successful with the development of novel nanoparticles that have a large capacity for flexible, quick drug design and manufacture based on tumour genetic profiles [1]. Opens new vistas for cancer treatment because of the sophisticated design and different mechanisms of delivery of drugs known for different nanodrugs, including lipid nanoparticles, polymer conjugated verbs, micelles, polymeric nanoparticles, carbon-based, and nanocrystals.

Nanodynamic Therapy (NDT), which is triggered by either endogenous or exogenous catalysts on nanosensitizers, can based evaluation radicals for accomplishing effective illness nano therapies with mitigated adverse reactions and endowed disease specificity [2,3]. This is made possible and promoted by the quick knowledge development of nanomedicine and nano biotechnology. Traditional light-activated photodynamic, one of the most prevalent NDT modalities is plagued by the crucial and insurmountable problems of the limited skin depth of light as well as the photo toxicity of the sensitizers [4,5].

Versatile nanoparticle NDTs have been investigated to overcome these challenges in order to meet a variety of biomedical applications, which heavily rely on the physicochemical features of the included nanomedicines and nanosensitizers. Sonodynamic Therapy (SDT), Piezoelectric Dynamics Therapy (PZDT), and potential anticancer treatment are examples of these different NDTs [6]. Here, the fundamental therapeutic idea and optimization strategy for enhancing disease-therapeutic effectiveness and biosafety plays crucial roles, functions, as well as biological effects of nanomaterials for facilitating the therapeutic process of NDTs. Throughout the past few decades, enthusiasm in nanomedicine for tumour therapeutic applications has increased substantially. Nevertheless, before these nanomedicines can reach their target, they must pass through a number of physiological obstacles that are inherent to the Tumour Microenvironment (TME) [7]. Every cancer patient is distinctive because to the intrinsic tumour genetic/phenotypic differences and intratumor heterogeneity that offer distinct clues to each cancer type. This creates new difficulties in developing clinically effective treatments using nanotechnology-based technologies.

CONCLUSION

Understanding the complex interaction among TME individuals and the intricate processes involved is crucial for the development of effective treatment methods since they serve as crucial targets for stopping tumour growth. With new technology and formulations being developed for a variety of illness situations, nanomedicine is still expanding. Despite the fact that most development focuses on the use of injection nanomedicines for the treatment of neoplasms, there are a number of formulations utilizing nanotechnology that may be given orally for noncancerous indications.

These nanomedicine remedies were created to deliver drugs locally or systemically throughout the gastrointestinal tract. RNA therapies have been successfully delivered into the liver using nizable lipid nanoparticles. The development of Lipid Nanoparticles (LNP) formulations for the selective transport of RNA into certain kinds of liver, such as hepatic and hepatic sinusoidal endothelial cells, is still a major problem. Here, modified LNPs for RNA transport into Liver Sinusoidal Endothelial Cells (LSECs) and hepatocytes. For the ApoE-mediated cellular absorption *via* low-density lipoprotein receptors to transfer mRNA to hepatocytes specifically, the impacts of particle diameter and polyethylene glycol-lipid concentration in the LNPs were assessed.

REFERENCES

1. Kumar A, Nanda A. Nano cocrystals: Crystal engineering from a nanotechnological perspective. Curr Pharm Des. 2021;27(21): 2445-2453.
2. Cote B, Rao D, Alani AW. Nanomedicine for drug delivery throughout the alimentary canal. Mol Pharm. 2021;19(8):2690-2711.

Correspondence to: Ruojiee Zhang, Department of Pharmaceutics, University of Cairo, Giza, Governorate, Egypt, E-mail: Ruojiee@hu.edu

Received: 01-Jan-2023, Manuscript No. JNBD-23-22452; **Editor assigned:** 06-Jan-2023, PreQC No. JNBD-23-22452 (PQ); **Reviewed:** 25-Jan-2023, QC No. JNBD-23-22452; **Revised:** 03-Feb-2023, Manuscript No. JNBD-23-22452 (R); **Published:** 13-Feb-2023, DOI: 10.4172/2155-983X.23.13.183

Citation: Zhang R (2023) Role of Nanomedicine in Drug Delivery System. J Nanomedicine Biotherapeutic Discov.13:183.

3. Han Y, Wen P, Li J, Kataoka K. Targeted nanomedicine in cisplatin-based cancer therapeutics. J Controlled Release. 2022.
4. Qiu M, Tang Y, Chen J, Muriph R, Ye Z, Huang C, et al. Lung-selective mRNA delivery of synthetic lipid nanoparticles for the treatment of pulmonary lymphangioleiomyomatosis. Proc Natl Acad Sci. 2022;119(8):e2116271119.
5. Lokugamage MP, Vanover D, Beyersdorf J, Hatit MZ, Rotolo L, Echeverri ES, et al. Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs. Nat Biomed Eng. 2021;5(9):1059-1068.
6. Chen S, Wu Y, Lortie F, Bernard J, Binder WH, Zhu J. Hydrogen-bonds-mediated nanomedicine: Design, synthesis, and applications. Macromol Rapid Commun. 2022;43(18):2200168.
7. Ouyang J, Rao S, Liu R, Wang L, Chen W, Tao W, et al. 2D materials-based nanomedicine: From discovery to applications. Adv Drug Deliv Rev. 2022:114268.